secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001193125-23-095317
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD posts $1.1M net income from continuing ops in FY2022 vs loss of $79.3M in 2021
--------------------------------------------------------------------------------

- License revenue surged to $70.0M from $2.6M, driven by $140M upfront from Mayne Pharma transaction.
- Company repaid all $188.3M debt, redeemed Series A preferred stock, and has $38.1M cash on hand.
- Discontinued ops generated $80.7M product revenue; net income of $110.9M vs loss in 2021.
- Reduced to one full-time employee; transition to virtual royalty model from Mayne Pharma license.
- Eligible for up to $30M milestones and 7.5%-8% royalties for 20 years with $3M minimum annual royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/0001193125-23-095317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/d485631d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-095317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer